100 related articles for article (PubMed ID: 25124560)
1. TRAIL mediated signaling in pancreatic cancer.
Nogueira DR; Yaylim I; Aamir Q; Kahraman OT; Fayyaz S; Kamran-ul-Hassan Naqvi S; Farooqi AA
Asian Pac J Cancer Prev; 2014; 15(15):5977-82. PubMed ID: 25124560
[TBL] [Abstract][Full Text] [Related]
2. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
[TBL] [Abstract][Full Text] [Related]
3. TRAIL mediated signaling as a double-edged sword in pancreatic cancer: Analysis of brighter and darker sides of the pathway.
Farooqi AA; Zahid R; Maryam A; Naureen H; Attar R; Sabitaliyevich UY; Konysbayevna KK
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):215-220. PubMed ID: 32538774
[TBL] [Abstract][Full Text] [Related]
4. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
5. Restoring TRAIL mediated signaling in ovarian cancer cells.
Farooqi AA; Yaylim I; Ozkan NE; Zaman F; Halim TA; Chang HW
Arch Immunol Ther Exp (Warsz); 2014 Dec; 62(6):459-74. PubMed ID: 25030086
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
[TBL] [Abstract][Full Text] [Related]
7. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
8. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
Tanaka R; Tomosugi M; Horinaka M; Sowa Y; Sakai T
PLoS One; 2015; 10(5):e0125779. PubMed ID: 25955843
[TBL] [Abstract][Full Text] [Related]
9. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
12. Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer.
Mert U; Sanlioglu AD
Cell Mol Life Sci; 2017 Jan; 74(2):245-255. PubMed ID: 27510421
[TBL] [Abstract][Full Text] [Related]
13. Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer.
Byeon HJ; Choi SH; Choi JS; Kim I; Shin BS; Lee ES; Park ES; Lee KC; Youn YS
Acta Biomater; 2014 Jan; 10(1):142-50. PubMed ID: 24021228
[TBL] [Abstract][Full Text] [Related]
14. Auriculasin sensitizes primary prostate cancer cells to TRAIL-mediated apoptosis through up-regulation of the DR5-dependent pathway.
Cho HD; Gu IA; Won YS; Moon KD; Park KH; Seo KI
Food Chem Toxicol; 2019 Apr; 126():223-232. PubMed ID: 30817944
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
16. New Frontiers in Promoting TRAIL-Mediated Cell Death: Focus on Natural Sensitizers, miRNAs, and Nanotechnological Advancements.
Farooqi AA; Gadaleta CD; Ranieri G; Fayyaz S; Marech I
Cell Biochem Biophys; 2016 Mar; 74(1):3-10. PubMed ID: 26972296
[TBL] [Abstract][Full Text] [Related]
17. TRAIL enhances quinacrine-mediated apoptosis in breast cancer cells through induction of autophagy via modulation of p21 and DR5 interactions.
Das S; Nayak A; Siddharth S; Nayak D; Narayan S; Kundu CN
Cell Oncol (Dordr); 2017 Dec; 40(6):593-607. PubMed ID: 28936683
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAIL-induced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway.
Vondálová Blanárová O; Jelínková I; Szöor A; Skender B; Soucek K; Horváth V; Vaculová A; Andera L; Sova P; Szöllosi J; Hofmanová J; Vereb G; Kozubík A
Carcinogenesis; 2011 Jan; 32(1):42-51. PubMed ID: 21037225
[TBL] [Abstract][Full Text] [Related]
19. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.
Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H
Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630
[TBL] [Abstract][Full Text] [Related]
20. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
